Praxis Precision Medicines, Inc. (PRAX) earnings date
Feb 23, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | before open | 40 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Wed, May 13, 2026 | after close | 43 | 8-K |
| Q4 FY2025 | Thu, Feb 19, 2026 | before open | 50 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | before open | 36 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | before open | 35 | 8-K |
| Q1 FY2025 | Fri, May 2, 2025 | before open | 32 | 8-K |
| Q4 FY2024 | Fri, Feb 28, 2025 | before open | 59 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies (DEEs) expected in the fourth quarter of 2026 Cash and investments of approximately $1.3 billion as of September 30, 2026 maintain runway into 2028 Praxis to host an in-person and virtual Investor Day on November" exhibit |
| Q3 FY2026 | "Commercial launch preparations continue to advance, with the commercial leadership team in place and hiring of the field sales force expected to be completed in the fourth quarter of 2026." exhibit |
| Q3 FY2026 | "Praxis continues to review the study design of POWER3, its planned study of vormatrigine as a monotherapy, and expects to initiate in 2027." exhibit |
| Q3 FY2026 | "The Company’s cash, cash equivalents and marketable securities as of September 30, 2026 are expected to fund operations into 2028." exhibit |
| Q2 FY2026 | "Document Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027 Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026 FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and rel" exhibit |
| Q2 FY2026 | "NDA review is progressing as expected, with a PDUFA date of January 29, 2027." exhibit |
| Q2 FY2026 | "Enrollment in the EMBRAVE3 registrational trial is progressing, with topline results expected in 2027." exhibit |
| Q2 FY2026 | "Praxis remains on track to nominate development candidates for several early-stage ASO therapeutic initiatives in 2026." exhibit |
| Q2 FY2026 | "The Company’s cash, cash equivalents and marketable securities as of June 30, 2026 are expected to fund operations into 2028." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PRAX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PRAX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/PRAX/"><img src="https://veritasdata.dev/embed/PRAX.svg" alt="PRAX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/PRAX/)
Script
<script async src="https://veritasdata.dev/embed/PRAX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PRAX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.